Satellite Educational Symposia are independently developed, CME-accredited educational programs held in conjunction with the San Antonio Breast Cancer Symposium® (SABCS). Supported by organizations outside of SABCS, these sessions undergo a rigorous review process and are evaluated for their ability to provide educational content distinct from and/or complementary to the official SABCS scientific program.
Satellite Educational Symposia for SABCS 2026 will take place at the San Antonio Marriott Rivercenter during the symposium. Attendance is complimentary, but advance registration may be required and space may be limited.
Please note: Satellite Educational Symposia are not official programs of the San Antonio Breast Cancer Symposium®. Views expressed by presenters are their own and do not necessarily reflect those of SABCS, UT Health San Antonio, AACR or symposium partners.
2026 Satellite Schedule
- Physicians’ Education Resource: “SERDs in HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibition.”
- Research To Practice: Second Opinion: A Case-Based Exploration of Clinical Investigator Best Practices Related to the Management of HER2-Positive Breast Cancer
- Research To Practice: Second Opinion: A Case-Based Exploration of Clinical Investigator Best Practices Related to the Use of PI3K/AKT/mTOR Inhibitors in HR-Positive Breast Cancer
- Clinical Care Options: Next-Generation Oral SERDs in Adjuvant ER-Positive/HER2-Negative Early Breast Cancer: Interrogating the Evidence for Clinical Integration
- Answers in CME: The Overlooked Side of Breast Cancer Care: Managing Vasomotor Symptoms With Novel Nonhormonal Treatments
- Research To Practice: Second Opinion: A Case-Based Exploration of Clinical Investigator Best Practices Related to the Management of Triple-Negative Breast Cancer
- PeerView Institute for Medical Education: Mapping the Complex Testing and Treatment Terrain in HR+, HER2- MBC and EBC: Evidence-Based and Algorithm-Guided Solutions to Real-World Clinical Challenges
- Research To Practice: Second Opinion: A Case-Based Exploration of Clinical Investigator Best Practices Related to the Use of Oral SERDs in HR-Positive Breast Cancer
- Research To Practice: DATA & PERSPECTIVES: Clinical Investigators Review Best Practices Related to the Management of Localized HR-Positive Breast Cancer
- Clinical Care Options: TROP2-Directed Therapy in Metastatic Triple-Negative Breast Cancer: Expert Insights on Patient Selection, Sequencing, and Practical Management
Key Dates
| Date | Milestone |
|---|---|
| August 7, 2026 | Application Deadline |
| August 28, 2026 | Acceptance letters emailed |
| September 4, 2026 | Payment and signed letter of agreement |
| October 9, 2026 | Deadline to cancel, no refunds permitted upon approval. |